FIELD: chemistry.
SUBSTANCE: present invention relates to a compound which is a fibroblast activation protein inhibitor modified with truncated blue YEVAN, or a pharmaceutically acceptable salt thereof, wherein its structure is represented by formula (II-1). Invention also discloses a method of producing a compound of formula (II-1), methods of producing a radiolabelled complex based on compound of formula (II-1) and use of formula (II-1) in preparing drugs for radionuclide therapy or imaging tumours with high level of expression of FAP protein.
EFFECT: proposed compound and a radioactive label based on the structure of said compound are characterized by a considerably prolonged half-life in the bloodstream, as well as increased absorption, accumulation and retention time in the tumour, and are suitable for nuclide therapy and imaging of tumours with a high level of FAP expression.
6 cl, 23 dwg, 1 ex
(II-1)
| Title | Year | Author | Number |
|---|---|---|---|
| DUAL TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN αβ, METHOD FOR PRODUCTION AND USE THEREOF | 2023 |
|
RU2838403C1 |
| COMPOUND HAVING TARGETED EFFECT ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2022 |
|
RU2832300C2 |
| DUAL TARGETING COMPOUND, METHOD FOR ITS PREPARATION AND USE | 2022 |
|
RU2838179C2 |
| FAP INHIBITOR | 2019 |
|
RU2797409C2 |
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
| CONJUGATED BISPHOSPHONATES FOR DIAGNOSING AND TREATING BONE DISEASES | 2015 |
|
RU2742660C2 |
| RADIOLABELLED GRPR ANTAGONIST FOR USE AS THERAPEUTIC AND DIAGNOSTIC AGENT | 2020 |
|
RU2839888C1 |
| NOVEL TUMOR ANTIGEN BINDING AGENTS AND USE THEREOF | 2019 |
|
RU2831681C2 |
| BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
| GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
